# SMART CARD: Metformin IR

**Card ID:** MED_DM_BIG_001
**Version:** 4.0
**Last Updated:** 2025-12-08

---

# ğŸ“± AT-A-GLANCE (20 seconds)

```
METFORMIN IR | 500mg â†’ 1000mg | TWICE DAILY | WITH FOOD
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Take: âœ“ Breakfast  âœ“ Dinner  (always with food)

ğŸŸ¢ Week 1-2:  500mg  +  500mg
ğŸŸ¡ Week 3-4:  500mg  + 1000mg
ğŸŸ£ Week 5+:  1000mg  + 1000mg  â† target

Watch: Stomach upset (normal first 2-4 wks) â†’ improves
Stop & call: Breathing trouble | Severe pain | Very cold

Labs: A1c q3mo | eGFR q3-6mo | B12 yearly
Goal: A1c < 7.0% in ~3 months
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
```

---

# ğŸ“± CONDENSED VIEW

> Essentials for everyday use.

## WHAT YOU'RE DOING
Taking Metformin twice daily to lower your blood sugar and protect your heart.

## WHY THIS MATTERS
**Your goal:** [Patient's own words - captured at intake]

**Why prescribed:** First-choice diabetes medication. Lowers blood sugar, protects heart, no weight gain.

**Evidence:** Grade A - Proven effective over 60 years, reduces complications by 32%.

## HOW TO DO IT
1. Take one pill **with breakfast**
2. Take one pill **with dinner**
3. **Always eat food** when you take it
4. Swallow whole with water

**Tip:** Keep pills next to your coffee maker or dinner plate.

## DOSE PROGRESSION

```
ğŸŸ¢ Week 1-2 â†’ 500mg AM  +  500mg PM   (starting)
ğŸŸ¡ Week 3-4 â†’ 500mg AM  + 1000mg PM   (building)
ğŸŸ£ Week 5+  â†’ 1000mg AM + 1000mg PM   (target)
```
*Advance only when tolerating well.*

## WHAT TO WATCH FOR

| Level | Signs | Action |
|-------|-------|--------|
| ğŸŸ¡ Normal | Upset stomach, loose stools | Wait 2-4 weeks, improves |
| ğŸŸ  Call doctor | GI issues >4 weeks, extreme tiredness | Schedule visit |
| ğŸ”´ Emergency | Trouble breathing, severe muscle pain, cold + slow heartbeat | Call 911 |

## DIFFICULTY
â­â­â˜†â˜†â˜† **Easy** - Twice daily pill with meals

## CHECK-INS

| When | What We'll Ask |
|------|----------------|
| Day 3 | How's your stomach? Taking with food? |
| Day 7 | Tolerating? Any barriers? |
| Day 14 | Ready to increase dose? |
| Month 1 | Adherence? Side effects? |
| Month 3 | A1c recheck - let's see your progress! |

## COMMUNITY
â­ 4.2/5 | 72% still taking at 6 months | 65% reached their goal

---

# ğŸ“‹ EXPANDED VIEW

> Full details for clinicians, advanced users, and curious patients.

---

## WHO

| Role | Responsibility |
|------|----------------|
| Patient | Take as prescribed, report side effects, communicate barriers |
| Prescriber | Prescribe, adjust dose, monitor labs |
| Pharmacist | Dispense, counsel on use |
| Care Team | Check-ins, education, troubleshooting |
| Family | Reminders, watch for warning signs |

---

## WHAT

| Field | Value |
|-------|-------|
| Medication | Metformin Hydrochloride (Glucophage) |
| Class | Biguanide |
| Starting Dose | 500mg twice daily |
| Target Dose | 1000mg twice daily |
| Maximum | 2550mg/day |
| Form | Oral tablet |

---

## WHEN

**Schedule:** Twice daily with breakfast and dinner
**Duration:** Ongoing (chronic therapy)
**Missed dose:** Take with next meal. Never double up.

---

## WHERE

**Setting:** Home, with meals
**Storage:** Room temperature, away from moisture

---

## WHY (Mechanism)

1. **Reduces** liver glucose production
2. **Improves** muscle insulin sensitivity
3. **Slows** intestinal glucose absorption

**Benefits:** No hypoglycemia risk (monotherapy). Weight neutral or slight loss. Cardiovascular protection.

---

## HOW

**Instructions:**
1. Take with first bite of food (not before eating)
2. Swallow whole with water
3. Same times daily for consistency

**If stomach upset:**
- Eat more food with it
- Avoid greasy foods initially
- Usually resolves by week 3-4
- Extended-release (ER) option if persistent

---

## MEASURE

| Test | Frequency | Purpose |
|------|-----------|---------|
| A1c | q3mo â†’ q6mo when stable | 3-month glucose average |
| eGFR | q3-6mo initially â†’ annually | Kidney safety |
| B12 | Annually | Metformin lowers B12 absorption |

**What you may notice:** More energy, fewer cravings, possible mild weight loss

---

## TARGET

| Metric | Goal | Timeline |
|--------|------|----------|
| A1c | < 7.0% | 3-6 months |
| A1c reduction | 1.0-1.5% | Expected drop |
| Glucose improvement | Noticeable | 2-4 weeks |

---

## SAFETY

### Common Side Effects (Temporary: 30-50%)
- Stomach upset, nausea
- Diarrhea
- Metallic taste

### Hold Medication If:
| Situation | Action |
|-----------|--------|
| Severely dehydrated/ill | Hold until resolved |
| IV contrast imaging | Hold 48h before AND after |
| Surgery (NPO) | Hold day of procedure |

### Drug Interactions:
| Substance | Guidance |
|-----------|----------|
| Alcohol | Limit 1-2 drinks/day |
| NSAIDs (chronic) | Monitor kidney function |
| IV contrast | Hold protocol above |

---

## DECISION PATHWAY

```
START: Taking Metformin at target dose (1000mg BID)
         â”‚
         â–¼
    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
    â”‚     MONTH 3: Check A1c                  â”‚
    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
         â”‚
    â”Œâ”€â”€â”€â”€â”´â”€â”€â”€â”€â”
    â–¼         â–¼
 AT GOAL   NOT AT GOAL
 (< 7.0%)  (â‰¥ 7.0%)
    â”‚         â”‚
    â–¼         â–¼
Continue   Add SGLT2i or GLP-1
Extend     (empagliflozin, semaglutide)
intervals
    â”‚
    â–¼
    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
    â”‚     ONGOING MONITORING                  â”‚
    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
    â”‚
    â”œâ”€â”€ GI symptoms >4 weeks? â†’ Switch to ER formulation
    â”œâ”€â”€ eGFR declining >25%? â†’ Clinician review
    â”œâ”€â”€ eGFR < 30? â†’ Discontinue
    â””â”€â”€ Adherence < 50%? â†’ Barrier assessment
```

---

## FOLLOW-UP SCHEDULE

### Phase 1: Initiation (Days 1-14)
| Day | Method | Focus |
|-----|--------|-------|
| 3 | App/text | GI tolerance, taking with food? |
| 7 | App/phone | Tolerating? Barriers? |
| 14 | App/phone | Ready to advance dose? |

### Phase 2: Titration (Weeks 3-12)
| When | Method | Focus |
|------|--------|-------|
| Week 4 | Phone/visit | Dose increase to target |
| Week 8 | App | Adherence check |
| Month 3 | Lab + visit | A1c recheck |

### Phase 3: Maintenance (Month 4+)
| When | Method | Focus |
|------|--------|-------|
| Monthly | App | Quick adherence check |
| q3-6mo | Lab + visit | A1c, eGFR |
| Yearly | Comprehensive | B12, full medication review |

---

## IF YOU'RE STRUGGLING

**Missed days?** Restart with next meal. No doubling.
**Missed week+?** Restart at current dose. Mention at next check-in.

### Common Barriers & Solutions

| Barrier | Solution |
|---------|----------|
| Forgetting | Pill organizer, phone alarm, anchor to meals |
| GI issues | More food, wait 3-4 weeks, switch to ER |
| "Not feeling different" | Works silently - A1c shows the change |
| Travel/schedule changes | Take with any meal; timing flexible |

---

## YOUR PROGRESS

**Baseline:** A1c: _____ | Date started: _____

**Milestones:**
- [ ] First week completed
- [ ] Target dose reached (1000mg BID)
- [ ] First A1c recheck (Month 3)
- [ ] A1c at goal (< 7.0%)

---

## EVIDENCE

### Summary
Metformin is the most extensively studied diabetes medication with 60+ years of clinical use. Multiple large trials and every major guideline recommend it as first-line therapy. It reliably lowers blood sugar and, uniquely among diabetes drugs, has proven cardiovascular benefits.

### Grade: A (Strongest)

### Grading Criteria Met
- [x] Multiple systematic reviews/meta-analyses
- [x] Multiple large, well-designed RCTs with consistent results
- [x] Endorsed by all major guideline bodies (ADA, EASD, AACE)
- [x] Extensive real-world effectiveness data
- [x] Benefits clearly outweigh risks

### Key Studies

| Study | Finding |
|-------|---------|
| **UKPDS 34** (n=1,704, 10yr) | 32% reduction in complications, 36% reduction in mortality |
| **Cochrane Review** (35 RCTs) | A1c reduction 1.0-1.5% vs placebo |
| **ADA 2024 Guidelines** | "Preferred initial pharmacologic agent for T2DM" |

**NNT:** 14 (to prevent one complication over 10 years)

### Evidence Gaps
- Limited RCT data for eGFR 30-45
- No large head-to-head vs newer agents as first-line
- Optimal CV dosing not established

**Last Reviewed:** December 2024

---

## NOTES

### Feasibility Score: 75/100 (Clinician Reference)
| Factor | Impact |
|--------|--------|
| Base | 100 |
| GI effects | -15 |
| BID dosing | -5 |
| Lab monitoring | -5 |
| Affordable | +10 |
| No hypoglycemia | +5 |
| Weight neutral | +5 |

### Patient Confidence Assessment
*Ask at prescribing:* "On a scale of 0-10, how confident are you that you can take this medication twice daily with meals?"

| Score | Interpretation | Action |
|-------|----------------|--------|
| 8-10 | Ready | Proceed |
| 5-7 | Uncertain | Explore barriers |
| 0-4 | Concerned | Address before starting |

### Version History
| Version | Date | Changes |
|---------|------|---------|
| 4.0 | 2025-12-08 | Added At-a-Glance quick card, visual dose ladder, decision pathway flowchart, compressed expanded view |
| 3.0 | 2025-12-08 | Restructured for patient/clinician clarity; robust EVIDENCE section |
| 2.5 | 2025-12-07 | Added AI agent specifications |
| 1.0 | 2024-11-23 | Initial card |

---

# ğŸ”§ AI METADATA

<!--
Hidden from user interface.
Parsed by AI agents for decision-making.
Clinician override via interface dropdown.
-->

```yaml
# === IDENTIFIERS ===
card_id: MED_DM_BIG_001
generic: Metformin Hydrochloride
brand: Glucophage
class: Biguanide
path: Medical > Medications > Diabetes > Biguanides

# === AUTONOMY ===
autonomy:
  tier: 4  # Clinician-directed
  responsible_agent: AI_Pharmacist
  specialist_consult: AI_Endocrinologist
  approval_type: individual
  patient_can_initiate: false
  patient_can_adjust: false
  patient_can_pause: true  # AI alerts clinician
  patient_can_discontinue: false  # Requires approval

# === TAGS ===
tags:
  clinical: [diabetes, T2DM, metabolic, first_line]
  evidence: [grade_A, guideline_recommended, RCT_supported]
  properties: [oral, BID, titratable, chronic]
  systems: [metabolic, cardiovascular]

# === RELATED CARDS ===
related:
  alternative: MED_DM_BIG_002  # Metformin ER - if GI intolerant
  add_on:
    - MED_DM_SGLT2_001  # Empagliflozin - if CV/renal benefit needed
    - MED_DM_GLP1_001   # Semaglutide - if weight loss priority
  synergy:
    - DIAG_LAB_A1C      # A1c monitoring
    - BEHAV_NUT_xxx     # Nutrition cards
    - BEHAV_MOV_xxx     # Movement cards
  prerequisite: none
  leads_to: [SGLT2i, GLP1]  # If inadequate response

# === DOSING ===
dosing:
  forms: [500mg, 850mg, 1000mg]
  route: PO
  frequency: BID
  with_food: required
  start: 500mg BID
  target: 1000mg BID
  max: 2550mg/day
  titration:
    interval: 1-2 weeks
    increment: 500mg

# === CONTRAINDICATIONS ===
contraindications:
  - eGFR < 30
  - lactic_acidosis_history
  - acute_decompensated_HF
  - severe_hepatic_impairment

# === ADJUSTMENTS ===
adjustments:
  renal:
    - condition: eGFR 30-45
      action: max 1000mg/day, monitor q3mo
    - condition: eGFR 45-60
      action: full dose, monitor q3mo
  age:
    - condition: age > 75
      action: start 500mg daily, slow titration
  GI_history:
    - condition: prior_intolerance
      action: start 500mg daily, consider ER

# === HOLD CONDITIONS ===
hold:
  - condition: IV_contrast
    action: hold 48h before and after
    auto_resume: yes, if eGFR stable
  - condition: acute_illness_dehydration
    action: hold until resolved
  - condition: surgery_NPO
    action: hold day of procedure

# === INTERACTIONS ===
interactions:
  - drug: alcohol
    severity: moderate
    action: counsel limit 1-2 drinks
  - drug: NSAIDs_chronic
    severity: moderate
    action: monitor eGFR
  - drug: contrast_IV
    severity: high
    action: hold protocol

# === MONITORING ===
monitoring:
  A1c: {initial: q3mo, stable: q6mo}
  eGFR: {initial: q3mo, stable: annually}
  B12: annually

# === ALERTS ===
alerts:
  efficacy:
    - condition: A1c drop < 0.5% after 3mo max dose
      action: recommend add second agent
      urgency: routine
  safety:
    - condition: eGFR decline > 25%
      action: flag for clinician review
      urgency: urgent
    - condition: eGFR < 30
      action: discontinue, alert clinician
      urgency: urgent
  tolerability:
    - condition: GI symptoms > 4 weeks
      action: recommend switch to ER
      urgency: routine
  adherence:
    - condition: missed 3+ consecutive
      action: barrier assessment
      urgency: routine
    - condition: adherence < 50% over 14 days
      action: escalate to care team
      urgency: soon

# === PROACTIVE CHECK-INS ===
checkins:
  initiation:
    - day: 3
      questions: [gi_tolerance, taking_with_food]
      escalate_if: severe_gi
    - day: 7
      questions: [tolerating, barriers]
      escalate_if: persistent_gi, non_adherence
    - day: 14
      questions: [ready_to_advance]
      action_if_ready: advance_dose
  titration:
    - week: 4
      focus: dose_advancement
    - week: 8
      focus: adherence_check
  maintenance:
    - interval: monthly
      focus: adherence_symptoms
    - interval: quarterly
      focus: a1c_egfr_comprehensive

# === LIFECYCLE ===
lifecycle:
  initiation:
    duration: days 1-14
    focus: tolerability
    success: tolerating BID, no severe GI
  maintenance:
    adherence_target: 80%
    review: monthly app, quarterly visit
  de_loading:
    graduation:
      criteria: A1c < 5.7% sustained 6mo + lifestyle
      action: supervised taper
      rare: true
    transition_gi:
      criteria: GI intolerable > 4 weeks
      action: switch to MED_DM_BIG_002
    transition_efficacy:
      criteria: A1c not at goal after 3mo max dose
      action: add SGLT2i or GLP-1
    discontinue:
      criteria: [eGFR < 30, lactic_acidosis, patient_refusal]
      action: stop, document, alternative

# === EVIDENCE (AI Reference) ===
evidence:
  grade: A
  last_reviewed: 2024-12
  primary_guideline: ADA_Standards_2024
  key_trials: [UKPDS_34, HOME]
  meta_analyses: [Cochrane_2012]
  evidence_gaps: [eGFR_30-45_RCT, first_line_vs_newer_agents]

# === FEASIBILITY ===
feasibility:
  score: 75
  difficulty: easy  # Patient-facing
  deductions: {GI_effects: -15, BID_dosing: -5, monitoring: -5}
  boosters: {affordable: +10, no_hypoglycemia: +5, weight_neutral: +5}
```

---

**END OF CARD**

*Template: Universal Card Template v4.0*
